Conventional induction treatments do not influence overall survival in multiple myeloma

British Journal of Haematology

Volumn 96, Issue 2, 1997, Pages 333-337

  Boccadoro, Mario ^b,c   Palumbo, Antonio ^b   Argentino, Chiara ^b   Dominietto, Alida ^b   Frieri, Roberto ^b   Avvisati, Giuseppe ^a   Comotti, Benedetto ^a   Lauta, Vito Michele ^a   Liberati, Marina ^a   Marmont, Filippo ^a   Musto, Pellegrino ^a   Tribalto, Maurizio ^a   Pileri, Alessandro ^b  

^a Italian Multiple Myeloma Study Group   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Cattedra di Ematologia   (Italy)

Author keywords

chemotherapy; multiple myeloma; overall survival; remission duration

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; SURVIVAL;

EID: 8044259007     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.d01-2041.x     Document Type: Article

References (21)

1. Alexanian, R., Dimupoulos, M.A., Hester, J., Delasalle, K.B. & Champlin, R. (1994) Early myeloablative therapy for multiple myeloma. Blood, 84, 4278-4282.
2. Alexanian, R., Haut, A. & Khan, A. (1969) Treatment of multiple myeloma: combination chemotherapy with different melphalan dose regimens. Journal of the American Medical Association, 208, 1680-1685.
3. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P. Maissoneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91-97.
4. Bladé, J., San Miguel, J.F., Alcalà, A., Maldonado, J., Sanz, M.A., Conde, J.G., Moro, M.J., Alonso, C., Besalduch, J., Zubizarreta, A., Besses, C., Brito, G.G., Martin, J.H., Calvo, J.F., Rubio, D., Ortega, F., Jimenez, R., Colominas, P., Faura, M.V, Font, L., Tortosa, J., Domingo, A., Fontanillas, M., Rozman, C. & Estapè, J. (1993) Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. Journal of Clinical Oncology, 11, 1165-1171.
5. Boccadoro, M., Marmont, F., Tribalto, M., Avvisati, G., Andriani, A., Barbui, T., Cantonetti, M., Carotenuto, M., Comotti, B., Dammacco, F., Frieri, R., Gallamini, A., Gallone, G., Giovangrossi, P., Grignani, F., Lauta, V.M., Liberati, M., Musto, P., Neretto, G., Petrucci, M.T., Resegotti, L., Pileri, A. & Mandelli, F. (1991) Multiple myeloma: alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan and prednisone (MP) even in high-risk patients. Journal of Clinical Oncology, 9, 444-448.
6. Cooper, M.R., McIntyre, O.R., Propert, K.J., Kochwa, S., Anderson, K., Coleman, M., Kyle, R.A., Prager, D., Rafla, S. & Zimmer, B. (1986) Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB study. Journal of Clinical Oncology, 4, 1331-1339.
7. Corradini, P., Voena, C., Astolfi, M., Ladetto, M., Tarella. C., Boccadoro, M. & Pileri, A. (1995) High dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detactable in bone marrow and peripheral blood harvests, and after autografting. Blood, 85, 1596-1602.
8. Dimopoulos, M.A., Hester, J., Huh, Y., Champlin, R. & Alexanian, R. (1994a) Intensive chemotherapy with blood progenitor transplantation for primary resistant myeloma. British Journal of Haematology, 87, 730-734.
9. Dimopoulos, M.A., Weber, D.M., Hester, J., Delasalle, K., Champlin, R. & Alexanian, R. (1994b) Intensive sequential therapy for VAD-resistant multiple myeloma. Leukemia and Lymphomas. 13, 479-484.
10. Durie, B.G.M. & Salmon, S.E. (1977) Multiple myeloma, macroglobulinaemia and monoclonal gammopathies. Recent Advances in Haematology (ed. by A. V. Hoffbrand, M. C. Brown and J. Hirsch), p. 243. Churchill Livingstone, Edinburgh.
11. Fermand, J.P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Dreyfus, F., Troussard, X., Brechignac, S., Mariette, X. & Brouet, J.C. (1995) High-dose therapy (HDT) and autologous blood stem cells transplantation (ABSCT) versus conventional chemotherapy with HDT rescue in multiple myeloma (MM): results of a prospective randomized trial. Blood, 86. (Suppl. 1) (abstract).
12. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
13. Lenhart, R.E., Enterline, J.P., Crowley, J. & Ho, G.Y.F. (1987) The effect of distance from primary treatment centers on survival among patients with multiple myeloma. Journal of Clinical Oncology, 5, 1640-1645.
14. MacLennan, I.C.M., Chapman, C., Dunn, J. & Kelly, K. (1992) Combined chemotherapy with ABMC versus melphalan for treatment of myelomatosis. Lancet, 339, 200-205.
15. Peest, D., Deicher, H. & Coldeway, R. (1988) Induction and maintenance therapy in multiple myeloma: a multicentre trial of MP versus VMCP European Journal of Cancer and Clinical Oncology, 24, 1061-1067.
16. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.G. (1976) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. British Journal of Cancer, 34, 585-612.
17. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.C. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. British Journal of Cancer, 35, 1-39.
18. 2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment. European Journal of Haematology, 42, 233-237.
19. Salmon, S.E., Haut, A., Bonnet, J.D., Amare, M., Weick, J.K., Durie, B.G.M. & Dixon, D.O. (1983) Alternating combination chemotherapy improves survival in multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology, 1, 453-461.
20. Tricot, G., Jagannath, S., Vesole, D.H., Crowley, J. & Barlogie, B. (1995) Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplantation, 16, 7-11.
21. Vesole, D.H., Barlogie, B., Jagannath, S., Cheson, B., Tricot, G., Alexanian, R. & Crowley, J. (1994) High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood, 84, 950-956.